Tenascin

• 

  Subject Areas on Research

  • A novel alternative splice domain in zebrafish tenascin-C. 
  • A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. 
  • A tenascin knockout with a phenotype. 
  • Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. 
  • Articular chondrocyte tenascin-C production and assembly into de novo extracellular matrix. 
  • Asymmetric localization of numb autonomously determines sibling neuron identity in the Drosophila CNS. 
  • Backbone dynamics of homologous fibronectin type III cell adhesion domains from fibronectin and tenascin. 
  • Binding of hexabrachion (tenascin) to the extracellular matrix and substratum and its effect on cell adhesion. 
  • Binding of tenascin-C to soluble fibronectin and matrix fibrils. 
  • Biochemical and structural studies of tenascin/hexabrachion proteins. 
  • Bronchial epithelial injury in the context of alloimmunity promotes lymphocytic bronchiolitis through hyaluronan expression. 
  • Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response. 
  • Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response. 
  • Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. 
  • Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. 
  • Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. 
  • Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. 
  • Colocalization of tenascin with versican, a hyaluronate-binding chondroitin sulfate proteoglycan. 
  • Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. 
  • Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia. 
  • Designing an extracellular matrix protein with enhanced mechanical stability. 
  • Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. 
  • Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. 
  • Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. 
  • Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. 
  • Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. 
  • Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. 
  • Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. 
  • Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. 
  • Evolution of the tenascin family--implications for function of the C-terminal fibrinogen-like domain. 
  • Extracellular annexin II. 
  • Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. 
  • Gene knockouts of c-src, transforming growth factor beta 1, and tenascin suggest superfluous, nonfunctional expression of proteins. 
  • Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. 
  • Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. 
  • Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. 
  • High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. 
  • Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. 
  • Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. 
  • Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. 
  • Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. 
  • Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis. 
  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. 
  • Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. 
  • Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. 
  • Localization and quantitation of hexabrachion (tenascin) in skin, embryonic brain, tumors, and plasma. 
  • Localization of a cryptic binding site for tenascin on fibronectin. 
  • Localization of tenascin in uterine sarcomas and partially transformed endometrial stromal cells. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells. 
  • Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. 
  • Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. 
  • Pervasive conformational fluctuations on microsecond time scales in a fibronectin type III domain. 
  • Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. 
  • Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. 
  • Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Purification of hexabrachion (tenascin) from cell culture conditioned medium, and separation from a cell adhesion factor. 
  • Rapid epithelialisation of fetal wounds is associated with the early deposition of tenascin. 
  • Rare variants in tenascin genes in a cohort of children with primary vesicoureteric reflux. 
  • Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. 
  • Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. 
  • Severe airway epithelial injury, aberrant repair and bronchiolitis obliterans develops after diacetyl instillation in rats. 
  • Structural organization of the human insulin receptor ectodomain. 
  • Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. 
  • TGF-beta regulates expression of tenascin alternative-splicing isoforms in fetal rat lung. 
  • TNXB mutations can cause vesicoureteral reflux. 
  • Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. 
  • Tenascin expression in human glioma cell lines and normal tissues. 
  • Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. 
  • Tenascin in rat lung development: in situ localization and cellular sources. 
  • Tenascin is induced at implantation sites in the mouse uterus and interferes with epithelial cell adhesion. 
  • Tenascin knockout mice: barrels, boundary molecules, and glial scars. 
  • Tenascin supports lymphocyte rolling. 
  • Tenascin-C expression and distribution in cultured human chondrocytes and chondrosarcoma cells. 
  • Tenascin-C expression in dystrophin-related muscular dystrophy. 
  • Tenascin-C in rat lung: distribution, ontogeny and role in branching morphogenesis. 
  • Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. 
  • Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. 
  • Tenascin-C knockout mouse has no detectable tenascin-C protein. 
  • Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. 
  • Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. 
  • Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. 
  • Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. 
  • Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. 
  • The CXC chemokine cCAF stimulates precocious deposition of ECM molecules by wound fibroblasts, accelerating development of granulation tissue. 
  • The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids. 
  • The clinical significance of tenascin-C splice variant expression in chondrosarcoma. 
  • The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. 
  • The molecular elasticity of the extracellular matrix protein tenascin. 
  • Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. 
  • Transcriptional response to hypoxia in human tumors. 
  • Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. 
  • Treatment of newly diagnosed glioblastoma multiforme. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. 
  • Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. 
  • Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin alpha 8 beta 1 receptor interactions with tenascin: murine alpha 8 beta 1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C. 
  • Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. 
• 

  Keywords of People

  • Erickson, Harold Paul, James B. Duke Professor of Cell Biology, Biomedical Engineering
  • Liu, Yutao, Adjunct Assistant Professor in the Department of Medicine, Medicine, Medical Genetics
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology